WO2012094437A3 - Nicotinic receptor non-competitive antagonists - Google Patents

Nicotinic receptor non-competitive antagonists Download PDF

Info

Publication number
WO2012094437A3
WO2012094437A3 PCT/US2012/020246 US2012020246W WO2012094437A3 WO 2012094437 A3 WO2012094437 A3 WO 2012094437A3 US 2012020246 W US2012020246 W US 2012020246W WO 2012094437 A3 WO2012094437 A3 WO 2012094437A3
Authority
WO
WIPO (PCT)
Prior art keywords
competitive antagonists
nicotinic receptor
receptor non
methods
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/020246
Other languages
French (fr)
Other versions
WO2012094437A2 (en
Inventor
Srinivasa Rao Akireddy
Scott R. Breining
Matt S. Melvin
Srinivasa V. Murthy
Anatoly A. Mazurov
Balwinder Singh Bhatti
Jon-Paul Strachan
Ronald Joseph Heemstra
Todd Showalter
Yunde Xiao
Philip S. Hammond
Lan Miao
David Kombo
Daniel Yohannes
Jason Speake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gyre Therapeutics Inc
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP12731898.8A priority Critical patent/EP2661421A2/en
Priority to PH1/2013/501453A priority patent/PH12013501453A1/en
Priority to CA2823848A priority patent/CA2823848A1/en
Priority to KR1020137020674A priority patent/KR20140038361A/en
Priority to JP2013548495A priority patent/JP2014510026A/en
Priority to MX2013007952A priority patent/MX2013007952A/en
Priority to CN2012800094116A priority patent/CN103402971A/en
Priority to BR112013017405A priority patent/BR112013017405A2/en
Priority to US13/978,583 priority patent/US20140288169A1/en
Application filed by Targacept Inc filed Critical Targacept Inc
Priority to SG2013052402A priority patent/SG191884A1/en
Priority to RU2013136851/04A priority patent/RU2013136851A/en
Publication of WO2012094437A2 publication Critical patent/WO2012094437A2/en
Publication of WO2012094437A3 publication Critical patent/WO2012094437A3/en
Priority to IL227319A priority patent/IL227319A0/en
Anticipated expiration legal-status Critical
Priority to IL230334A priority patent/IL230334A0/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/40—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/44—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing eight carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for their use, and their pharmaceutical compositions.
PCT/US2012/020246 2011-01-07 2012-01-05 Nicotinic receptor non-competitive antagonists Ceased WO2012094437A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
US13/978,583 US20140288169A1 (en) 2011-01-07 2012-01-05 Nicotinic receptor non-competitive antagonists
CA2823848A CA2823848A1 (en) 2011-01-07 2012-01-05 Nicotinic receptor non-competitive antagonists
KR1020137020674A KR20140038361A (en) 2011-01-07 2012-01-05 Nicotinic receptor non-competitive antagonists
JP2013548495A JP2014510026A (en) 2011-01-07 2012-01-05 Non-competitive antagonist of nicotine receptor
MX2013007952A MX2013007952A (en) 2011-01-07 2012-01-05 NON-COMPETITIVE ANTAGONISTS OF NICOTINIC RECEPTORS.
CN2012800094116A CN103402971A (en) 2011-01-07 2012-01-05 Nicotinic receptor non-competitive antagonists
BR112013017405A BR112013017405A2 (en) 2011-01-07 2012-01-05 non-competitive nicotinic receptor antagonists
EP12731898.8A EP2661421A2 (en) 2011-01-07 2012-01-05 Nicotinic receptor non-competitive antagonists
SG2013052402A SG191884A1 (en) 2011-01-07 2012-01-05 Nicotinic receptor non-competitive antagonists
PH1/2013/501453A PH12013501453A1 (en) 2011-01-07 2012-01-05 Nicotinic receptor non-competitive antagonists
RU2013136851/04A RU2013136851A (en) 2011-01-07 2012-01-05 NON-COMPETITIVE NICOTINE RECEPTOR ANTAGONISTS
IL227319A IL227319A0 (en) 2011-01-07 2013-07-04 Non-competitive nicotinic receptor antagonists
IL230334A IL230334A0 (en) 2011-01-07 2014-01-06 Nicotinic receptor non-competitive antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161430640P 2011-01-07 2011-01-07
US61/430,640 2011-01-07

Publications (2)

Publication Number Publication Date
WO2012094437A2 WO2012094437A2 (en) 2012-07-12
WO2012094437A3 true WO2012094437A3 (en) 2012-11-01

Family

ID=46457959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/020246 Ceased WO2012094437A2 (en) 2011-01-07 2012-01-05 Nicotinic receptor non-competitive antagonists

Country Status (16)

Country Link
US (1) US20140288169A1 (en)
EP (1) EP2661421A2 (en)
JP (1) JP2014510026A (en)
KR (1) KR20140038361A (en)
CN (1) CN103402971A (en)
BR (1) BR112013017405A2 (en)
CA (1) CA2823848A1 (en)
CL (1) CL2013001978A1 (en)
CO (1) CO6821933A2 (en)
IL (2) IL227319A0 (en)
MX (1) MX2013007952A (en)
PE (1) PE20140873A1 (en)
PH (1) PH12013501453A1 (en)
RU (1) RU2013136851A (en)
SG (1) SG191884A1 (en)
WO (1) WO2012094437A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883888A (en) * 1984-07-13 1989-11-28 The Procter & Gamble Company Oxa-fenchyl amines useful for preparing high intensity sweeteners
US20070142362A1 (en) * 2005-12-20 2007-06-21 Solvay Pharmaceuticals B.V. 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
US20090275651A1 (en) * 2005-09-17 2009-11-05 Speedel Experimenta Ag Alcanoic Acid Amides Substituted by Saturated O-Heterocycles
WO2010138842A1 (en) * 2009-05-29 2010-12-02 Xlterra, Inc. Ketal esters of anhydropentitols and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3514486A (en) * 1968-05-23 1970-05-26 Miles Lab 3-isopropylnorbornanamine
DE69524223T2 (en) * 1994-07-11 2002-08-22 Allergan Sales, Inc. BICYCLIC DERIVATIVES WITH RIGID INFORMATION AND ADAMANTANE AS ALPHA-2-ADRENERGIC BLOCKING AGENTS
US5986142A (en) * 1997-09-23 1999-11-16 Poli Industria Chimica Spa Process for preparing bicycloheptanamine compounds
WO2003018004A2 (en) * 2001-08-29 2003-03-06 Endo Pharmaceuticals, Inc. Analgetic pyrroline derivatives
US20080058345A1 (en) * 2004-01-06 2008-03-06 Tony George Combination Therapy with Mecamylamine for the Treatment of Mood Disorders
AU2005249494A1 (en) * 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7880007B2 (en) * 2004-11-29 2011-02-01 Vertex Pharmaceuticals Incorporated Bicyclic substituted phenyl piperidine modulators of muscarinic receptors
WO2006105035A2 (en) * 2005-03-28 2006-10-05 Vertex Pharmaceuticals Incorporated Muscarinic modulators
US20090264650A1 (en) * 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
DE602006010870D1 (en) * 2005-06-20 2010-01-14 Schering Corp PIPERIDINE DERIVATIVES SUITED AS ANTAGONISTS OF HISTAMINE H3
TW200730500A (en) * 2005-12-20 2007-08-16 Solvay Pharm Bv 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
TW200901983A (en) * 2007-05-24 2009-01-16 Wyeth Corp Azacyclylbenzamide derivatives as histamine-3 antagonists
WO2009146031A1 (en) * 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
WO2013026852A2 (en) * 2011-08-22 2013-02-28 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Derivatives of mecamylamine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4883888A (en) * 1984-07-13 1989-11-28 The Procter & Gamble Company Oxa-fenchyl amines useful for preparing high intensity sweeteners
US20090275651A1 (en) * 2005-09-17 2009-11-05 Speedel Experimenta Ag Alcanoic Acid Amides Substituted by Saturated O-Heterocycles
US20070142362A1 (en) * 2005-12-20 2007-06-21 Solvay Pharmaceuticals B.V. 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators
WO2010138842A1 (en) * 2009-05-29 2010-12-02 Xlterra, Inc. Ketal esters of anhydropentitols and uses thereof

Also Published As

Publication number Publication date
KR20140038361A (en) 2014-03-28
IL230334A0 (en) 2014-03-06
EP2661421A2 (en) 2013-11-13
WO2012094437A2 (en) 2012-07-12
CO6821933A2 (en) 2013-12-31
PH12013501453A1 (en) 2013-08-28
US20140288169A1 (en) 2014-09-25
PE20140873A1 (en) 2014-08-13
IL227319A0 (en) 2013-09-30
BR112013017405A2 (en) 2016-10-04
CL2013001978A1 (en) 2013-11-04
JP2014510026A (en) 2014-04-24
SG191884A1 (en) 2013-08-30
CA2823848A1 (en) 2012-07-12
MX2013007952A (en) 2013-08-21
CN103402971A (en) 2013-11-20
RU2013136851A (en) 2015-02-20

Similar Documents

Publication Publication Date Title
GB201017345D0 (en) Receptor antagonists
EP4268814A3 (en) Pharmaceutical composition for the treatment of dry eye
MX352881B (en) Methods and compounds useful in the synthesis of orexin-2 receptor antagonists.
IL230218A (en) Substituted azaheterocyclic compounds, their preparation and pharmaceutical compositions containing them
IL233592A0 (en) P2x4 receptor antagonist
EA201290940A1 (en) NEW CONNECTIONS AS SELECTIVE ANTAGONISTS OF NK3 RECEPTOR, PHARMACEUTICAL COMPOSITION AND METHODS OF THEIR USE FOR DAMAGE MEDIATED BY NK3 RECEPTORS
MY173521A (en) Trpv4 antagonists
EP2665707A1 (en) Mineralocorticoid receptor antagonists
MA34075B1 (en) A pharmaceutical composition containing pyrimidine derivatives
EP3020717A4 (en) P2x4 receptor antagonist
EP3137074A4 (en) Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
WO2014066799A3 (en) Modulators of resistant androgen receptor
EP2668160A1 (en) Trpm8 receptor antagonists
EP3046923A4 (en) Formulations for cgrp receptor antagonists
ZA201405959B (en) Novel neurokinin 1 receptor antagonist compounds
EP2617717A4 (en) P2x4 receptor antagonist
HK1218543A1 (en) Novel sulfonamide trpa1 receptor antagonists
IL228019A (en) Compounds as histamine h3 receptor ligands, pharmaceutical compositions, process of preparation and uses thereof
AP2012006630A0 (en) Disubstituted tetrahydofuranyl compounds as antagonists of the bradykinin B1 receptor
PL3004058T3 (en) Acetylcholinesterase inhibitor compounds and 5ht4 serotonergic receptor agonists, with promnesia effect, methods for the preparation thereof and pharmaceutical compositions containing same
PH12012502300A1 (en) Nicotinic receptor non-competitive antagonists
WO2012154879A3 (en) Autophagy inhibitors
PH12013500991A1 (en) 4-SUBSTITUTED-3-PHENYLSULFANYLMETHYL-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGLuR 2/3 ANTAGONISTS
WO2011091410A8 (en) Trpv4 antagonists
IL236473B (en) Derivatives of 1,5-dihydro-2-pyrrol-one as cholecystokinin receptor ligands

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12731898

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2823848

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013548495

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2013001978

Country of ref document: CL

Ref document number: 001526-2013

Country of ref document: PE

Ref document number: MX/A/2013/007952

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12013501453

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2012731898

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20137020674

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13186097

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2013136851

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2012204423

Country of ref document: AU

Date of ref document: 20120105

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13978583

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013017405

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013017405

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130705